Emerald Health Therapeutics Inc (CVE:EMH) Release Corporate Update


Emerald Health Therapeutics Inc (CVE:EMH) released a corporate update on its closed and oversubscribed purchased deal financing, and reprises its vision for development in 2017. Avtar Dhillon, MD, the Executive Chairman, reported that following their successful deal with Dundee Capital Partners, the company is well capitalized and set for a remarkable year of growth.

Directed by one of the market’s most experienced teams, the focus continues to be on downstream product advancement. From the first day, Emerald has managed with the mandate of improving health through cannabis science and it’s these values that will lead them as the company forge ahead with its aggressive and exciting growth initiatives.

The highlights

As Emerald has been targeting expansion, much of its R&D focus has comprised increasing product offerings and plant diversity, as well as enhancing on its grow, production, and standardization procedures in anticipation of a considerable scale up. As the eighth Licensed Producer and fifth applicant in Canada, from the start the focus has remained on cultivation quality over quantity supported by strong R&D.

Phase 1 expansion plans are ongoing to break ground in the first quarter and add more cultivation space. This will be an advanced purpose built facility with expected capacity in surplus of 5,000 kg a year. The company’s first harvest is projected in 2018 and will be set for sale upon licensing. Regarding Phase II expansion, Emerald intends to grow-up in a modular way, with 50,000 square feet addition to reduce the risk of product quality concerns.

Construction on Phase II to add an additional production area of 50,000 square feet is projected to commence shortly after the start of Phase I and will be set for production next year. Emerald has the capacity to establish total production space of 1 million square feet on its Metro Vancouver property.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.